Biopeople

Enlarged Supervisory Board

Enlarged Supervisory Board

05.11.2012 - British GPCR drug discovery specialist Heptares Therapeutics Ltd has named Roger M. Perlmutter to its Board of Directors.

Perlmutter brings in more than 30 years of experience in academic and pharmaceutical industry research. The physician began his academic career in 1979 at Massachusetts General Hospital. After working at the University of Washington's Howard Hughes Medical Institute from 1984-1997, he joined Merck&Co as VP Preclinical & Basic Research. In 2001, Perlmutter became VP of R&D at Amgen Inc., where he stayed until he retired in 2012.

http://www.european-biotechnology-news.com/people/bio-people/2012-2/roger-m-perlmutter.html

01.10.2012 siRNA specialist Silence Therapeutics plc (London/Berlin) has appointed Michael Khan to its board of directors as Chief Medical Advisor.

Khan, who currently teaches and works as an Associate Professor of Medicine at the University of Warwick, has a strong track record in clinical development of drugs targeting metabolic diseases and cancer. The previous head of molecular medicine at Warwick University is currently working on identifying novel tissue-based biomarkers for colorectal cancer, and the development of novel diagnostic tools.

18.09.2012 German oncology expert Wilex AG has altered its executive management board. Dr. Jan Schmidt-Brand, who arrived from Wilex daughter Heidelberg Pharma, stepped into the CFO role at Wilex at the beginning of September.

Schmidt-Brandt was Managing Director at Heidelberg Pharma, which develops antibody-drug conjugates, until that firm was taken over by Wilex in November 2010. From 1997-2001, the trained lawyer was Managing Director of the Austrian BASF-Pharma subsidiary EBEWE Arznei-mittel GmbH, where his responsibilities included finance and controlling. Prior to that, he held several positions at the BASF Group over a period of eight years. In his final position there he was an executive in the chemical giant's central tax department. At the beginning of August, the firm announced that current CFO Peter Llewellyn-Davies would be stepping down when his six-year contract expired. Wilex announced that he is planning to pursue new activities, but will continue to act for the company in an advisory capacity.

14.09.2012 French-US non-statistical clinical data analyses provider Ariana Pharma has hired Dr. Mariana Kuras as its Chief Technology Officer.

From 2004–2012, Kuras led research at Bio-systems International, where she was responsible for the development and validation of biomarker platform technologies with the help of anti-body array technologies. Previously, she worked at Pfizer Global Research and Development (Fresnes, France). Kuras holds a PhD in biophysics and computational biology from the University of Illinois at Urbana-Champaign in the US.

12.09.2012 Oslo-based Photocure ASA has named Erik Dahl as its new CFO.

The specialist for photodynamic skin and cancer therapy brings more than 20 years of experience in senior level financial management roles in both international public and private companies. He has a strong track record in corporate finance, legal and financial restructurings, M&A, IPOs and other capital market transactions.

04.09.2012 Portuguese API specialist Hovione (Loures) has named Dr. Conrad Winters as new Drug Product Development Director.

Dr Winters was previously with Merck in the USA and Canada and most recently with Xenon Pharmaceuticals Inc., where he held the position of Senior Director, Compound Properties Group. The pharmacist brings 18 years of experience in the pharmaceutical industry with a focus on managing the development of compounds from lead candidate optimisation to NDA submission and commercialisation. He has extensive experience in rational formulation design, based on fundamental understanding of material properties and the adaptation of particle properties to effect improved bioperformance. Winters has led cross functional global teams charged with the development of priority new chemical entities. He has contributed to and prepared documentation in support of many successful regulatory submissions.

31.08.2012 Swiss drug giant Roche AG has filled the leadership gap at its pharma division after its former head Pascal Soriot left the company to become CEO of British-Swedish pharma major AstraZeneca.

From 1 September, Daniel O’Day, currently COO at Roche Diagnostics, will step in. O’Day will be succeeded by Roland Diggelmann, currently Head of the Asia-Pacific Region within Roche Diagnostics who has been appointed as a new member of the Executive Committee by the Board of Directors. Daniel O’Day began his career in 1987 at Roche in the U.S. Pharmaceuticals organisation in Sales and Marketing. Following that, he held various positions in Roche Pharma in Switzerland, Japan, and Denmark. In 2006, O’Day joined Roche Diagnostics and became Head of the business area „Molecular Diagnostics“. On January 1 2010 he was appointed Chief Operating Officer for Roche’s global diagnostics business.

07.08.2012 German biotech Wilex AG will change its executive management board. Chief Financial Officer Peter Llewellyn-Davies has to leave the company upon the expiration of his six year contract on September 1st. Jan Schmidt-Brand will take over.

Schmidt-Brandt is currently the Managing Director of Wilex's subsidiary Heidelberg Pharma GmbH. He was the CEO of Heidelberg Pharma AG until the company was acquired by Wilex. From 1997 to 2001, he was Managing Director of the Austrian BASF-Pharma subsidiary, EBEWE Arzneimittel GmbH, where his responsibilities included finance and controlling. Prior to this, he held several positions at the BASF Group for a total of eight years, most recently as an executive in the central tax department. Schmidt-Brand is a member of the Board of BioDeutschland and Head of the Finance and Tax working group. Llewellyn-Davies will pursue new activities but continues to act as an advisor for the company. He will fully manage and complete the capital measure announced by Wilex on August 3. “Mr Llewellyn-Davies has made important contributions to the development of Wilex since joining the company prior to its IPO in 2006. We would like to thank him very much for his collaboration, which was both constructive and successful, and wish him great success in realizing his objectives”, said Professor Christof Hettich, Chairman of the Supervisory Board.

14.08.2012 Italian IT expert Massimiliano Claps is the new EMEA research director for the Government and Health Insights department, announced the International Data Corporation (IDC).

Claps will lead IDC’s ongoing research programmes for the government and healthcare sectors in Europe, the Middle East, and Africa. He will also be responsible for analysing key trends related to IT strategies and spending in European governments and healthcare provider organisations. 

After graduating in business administration at Milan’s Bocconi University, Claps worked as a junior consultant for the Monitor Group where he advised major multinationals in the food and beverage, construction, media and telecoms, and pharmaceutical industries. His career in the IT sector began with his first stint at the IDC: Between 2002 and 2007 he worked for the EMEA Government and Health Insights business as well as for a year with IDC Canada to fast-track their government research. Max Clap’s latest assignment was to head the government team of one of the world’s leading information technology research and advisory companies, Gartner, Inc. 

21.08.2012 Horizon Discovery appointed Richard Vellacott as its new Chief Financial Officer. Vellacott has over 15 years’ experience in working with life sciences companies, from start-ups to global pharmaceuticals.

Prior to joining Horizon, he was Vice President Finance at CSR plc. During his time at CSR, Vellacott had worldwide responsibility for finance, making significant contributions to the transformational acquisition and integration of NASDAQ-listed Zoran Corp., product portfolio management, R&D budgeting and business investment. Before this, he was a Director in Deloitte’s life sciences practice, where he specialised in capital market transactions including IPOs, M&A and fundraising on both the UK and the US markets. Horizon Discovery Limited (“Horizon”) is a leading provider of research tools to support the development of personalised medicines. 

17.08.2012 Dr. Ilka Diester has received the prestigious Boehringer Ingelheim FENS Research Award. The Frankfurt-based neurobiologist got a price money of €25,000 at the Forum of the Federation of European Neuroscience Societies in Barcelona.

The award was dedicated to her research at Ernst-Strüngmann-Institut where she and her team analyse sensomotoric circuits with help of optogenetic and electrophysiological tools. Their research aims at developing neuroprotheses which can compensate neuronal functional disorders. The price is sponsored by the FENS and Boehringer.

Vorherige Seite3/6Nächste Seite

Whitepaper

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • MEDIGENE (D)10.45 EUR7.51%
  • WILEX (D)3.65 EUR5.49%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • 4SC (D)4.59 EUR-6.33%
  • BAVARIAN NORDIC (D)41.82 EUR-6.28%
  • BIOFRONTERA (D)2.06 EUR-5.50%

TOP

  • DBV Technologies (F)52.75 EUR16.9%
  • Allergy Therapeutics (UK)23.50 GBP15.3%
  • BIOINVENT INTERNATIONAL AB (S)2.56 SEK12.8%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.68 EUR-28.8%
  • NORDIC NANOVECTOR (N)25.20 NOK-26.5%

TOP

  • 4SC (D)4.59 EUR345.6%
  • ADOCIA (F)65.40 EUR336.0%
  • WILEX (D)3.65 EUR319.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)8.85 SEK-70.6%
  • NEOVACS (F)1.10 EUR-69.3%

No liability assumed, Date: 03.07.2015

Current issue

All issues